Dexamethasone and Drug Resistance in Lung Cancer
Author Information
Author(s): Gassler N, Zhang C, Wenger T, Schnabel P A, Dienemann H, Debatin K-M, Mattern J, Herr I
Primary Institution: University of Heidelberg, Germany
Hypothesis
Does dexamethasone induce resistance to cisplatin and gemcitabine in lung carcinoma samples?
Conclusion
Dexamethasone induces resistance to cisplatin and gemcitabine in lung cancer cells, raising concerns about its combined use with chemotherapy.
Supporting Evidence
- DEX induced resistance toward cisplatin in all of 10 examined tumour samples.
- Similar results were found using gemcitabine as cytotoxic drug.
- Survival of drug-treated lung carcinoma cells in the presence of DEX was long-lasting.
- DEX enhanced basal viability in most of the 10 examined lung tumour samples.
Takeaway
Dexamethasone, a common drug used to help cancer patients, can make lung cancer cells resistant to chemotherapy, which means the treatment might not work as well.
Methodology
Cancer cells were isolated from lung tumor specimens and treated with cisplatin or gemcitabine in the presence or absence of dexamethasone, with cell viability assessed using the MTT assay.
Limitations
The study is limited by the small sample size and the need for more extensive clinical trials to confirm findings.
Participant Demographics
The study included 10 lung cancer patients with various histological types, including adenocarcinoma and squamous cell carcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website